MaxCyte Inc
Company Profile
Business description
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Contact
9713 Key West Avenue
Suite 400
RockvilleMD20850
USAT: +1 301 944-1700
E: ir@maxcyte.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
114
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,588.70 | 64.40 | 0.86% |
| CAC 40 | 6,927.12 | 347.83 | -4.78% |
| DAX 40 | 19,789.62 | 852.10 | -4.13% |
| Dow JONES (US) | 37,965.60 | 2,580.33 | -6.36% |
| FTSE 100 | 7,702.08 | 352.90 | -4.38% |
| HKSE | 19,828.30 | 3,021.51 | -13.22% |
| NASDAQ | 15,603.26 | 947.34 | -5.72% |
| Nikkei 225 | 32,943.58 | 1,807.00 | 5.80% |
| NZX 50 Index | 11,887.54 | 111.66 | 0.95% |
| S&P 500 | 5,062.25 | 11.83 | -0.23% |
| S&P/ASX 200 | 7,401.30 | 58.00 | 0.79% |
| SSE Composite Index | 3,096.58 | 245.43 | -7.34% |